Renal impairment at diagnosis in myeloma: patient characteristics, treatment and impact on outcomes. Results from the Australia and New Zealand Myeloma & Related Diseases Registry

Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor prognosis. The Australia and New Zealand Myeloma Registry was used to assess>1000 newly diagnosed MM patients, of whom 383 had RI at diagnosis. Patients who underwent autologous stem cell transplant (ASCT) despite RI had improved survival; potential factors for an inferior outcome include suboptimal use of bortezomib and ASCT.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 14, 2019 Category: Hematology Authors: P Joy Ho, Elizabeth M. Moore, Zoe K. McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon J. Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica M. Wo Tags: Original Study Source Type: research